1. Search Result
Search Result
Results for "

cachexia

" in MCE Product Catalog:

20

Inhibitors & Agonists

3

Peptides

1

Inhibitory Antibodies

1

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-12176B
    Aliskiren fumarate

    CGP 60536 fumarate; CGP60536B fumarate; SPP 100 fumarate

    Renin Autophagy Cancer Cardiovascular Disease
    Aliskiren fumarate is an orally active, highly potent and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren fumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia.
  • HY-12176
    Aliskiren

    CGP 60536; CGP60536B; SPP 100

    Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren is an orally active, highly potent and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren can be used for the research of hypertension, cardiovascular diseases and cancer cachexia.
  • HY-12176A
    Aliskiren hydrochloride

    CGP 60536 hydrochloride; CGP60536B hydrochloride; SPP 100 hydrochloride

    Renin Autophagy Cancer Cardiovascular Disease
    Aliskiren (CGP 60536; CGP60536B; SPP 100) hydrochloride is an orally active and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren hydrochloride can be used for the research of hypertension, cardiovascular diseases and cancer cachexia -.
  • HY-12177
    Aliskiren hemifumarate

    CGP 60536 hemifumarate; CGP60536B hemifumarate; SPP 100 hemifumarate

    Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren (CGP 60536; CGP60536B; SPP 100) hemifumarate is an orally active and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren hemifumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia.
  • HY-13676
    Megestrol acetate

    Progesterone Receptor Autophagy HIV Endocrinology Cancer
    Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway.
  • HY-148349
    PF-07258669

    Melanocortin Receptor Metabolic Disease Neurological Disease
    PF-07258669 is a melanocortin-4 receptor (MC4) antagonist. PF-07258669 can be used for the research of cachexia, anorexia, or anorexia nervosa.
  • HY-19884
    Relamorelin

    RM-131; BIM-28131

    GHSR Metabolic Disease
    Relamorelin (RM-131), a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin is centrally penetrant. Relamorelin increases growth hormone levels and accelerates gastric emptying. Relamorelin has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research.
  • HY-19884A
    Relamorelin acetate

    RM-131 acetate; BIM-28131 acetate

    GHSR Metabolic Disease
    Relamorelin (RM-131) acetate, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin acetate is centrally penetrant. Relamorelin acetate increases growth hormone levels and accelerates gastric emptying. Relamorelin acetate has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research.
  • HY-19884B
    Relamorelin TFA

    RM-131 TFA; BIM-28131 TFA

    GHSR Metabolic Disease
    Relamorelin (RM-131) TFA, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin TFA is centrally penetrant. Relamorelin TFA increases growth hormone levels and accelerates gastric emptying. Relamorelin TFA has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research.
  • HY-129531
    MuRF1-IN-1

    Others Neurological Disease
    MuRF1-IN-1 is a muscle ring finger 1 (MuRF1) inhibitor that attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia.
  • HY-18102
    GLPG0492

    Androgen Receptor Others
    GLPG0492 is a non-steroidal selective androgen receptor modulator (potency 12 nM). GLPG0492 has the potential for the research of musculo-skeletal diseases such as sarcopenia and cachexia.
  • HY-N0109
    Salidroside

    Rhodioloside

    mTOR Apoptosis Prolyl Endopeptidase (PREP) Cancer
    Salidroside is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.
  • HY-100186
    GSK-2881078

    Androgen Receptor Neurological Disease
    GSK 2881078 is a selective androgen receptor modulator potentially for the treatment of cachexia.
  • HY-B1834
    Megestrol

    Drug Metabolite Inflammation/Immunology
    Megestrol is a synthetic progestin and used for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with an acquired immunodeficiency syndrome diagnosis.
  • HY-B1834S1
    Megestrol-d5

    Drug Metabolite
    Megestrol-d5 is the deuterium labeled Megestrol. Megestrol is a synthetic progestin and used for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with an acquired immunodeficiency syndrome diagnosis[1][2].
  • HY-14820A
    Macimorelin acetate

    EP-1572 acetate; AEZS-130 acetate

    GHSR Cancer Endocrinology Neurological Disease
    Macimorelin (EP-1572) acetate, a GH secretagogue, is an orally active GHSR agonist. Macimorelin acetate stimulates GH release. Macimorelin acetate can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS).
  • HY-14820
    Macimorelin

    EP-1572; AEZS-130

    GHSR Cancer Endocrinology
    Macimorelin (EP-1572), a GH secretagogue, is an orally active GHSR agonist. Macimorelin stimulates GH release. Macimorelin can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS).
  • HY-P99241
    Ponsegromab

    PF 06946860

    TGF-beta/Smad Cancer
    Ponsegromab (PF 06946860) is a potent and selective humanized anti-GDF15 antibody inhibitor with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers.
  • HY-13676S
    Megestrol acetate-d3

    Progesterone Receptor Autophagy HIV Endocrinology Cancer
    Megestrol acetate-d3 is the deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway[1][2][3][4][5].
  • HY-13676S1
    Megestrol acetate-d3-1

    Progesterone Receptor Autophagy HIV Endocrinology Cancer
    Megestrol acetate-d3-1 is deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway[1][2][3][4][5].